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Valvular heart disease
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Aims Westernized countries face a growing burden of cardiovascular calciﬁcation and osteoporosis. Despite its vast clinical
signiﬁcance, the precise nature of this reciprocal relationship remains obscure. We hypothesize that cardiovascular
calciﬁcation progresses with inﬂammation and inversely correlates with bone tissue mineral density (TMD).
Methods
and results
Arterial, valvular, and bone metabolism were visualized using near-infrared ﬂuorescence (NIRF) molecular imaging
agents, targeting macrophages and osteogenesis. We detected signiﬁcant arterial and aortic valve calciﬁcation in
apoE
2/2 mice with or without chronic renal disease (CRD, 30 weeks old; n ¼ 28), correlating with the severity
of atherosclerosis. We demonstrated decreases in osteogenic activity in the femurs of apoE
2/2 mice when compared
with WT mice, which was further reduced with CRD. Three-dimensional micro-computed tomography imaging of
the cortical and cancellous regions of femurs quantiﬁed structural remodelling and reductions in TMD in apoE
2/2
and CRD apoE
2/2 mice. We established signiﬁcant correlations between arterial and valvular calciﬁcation and
loss of TMD (R
2 ¼ 0.67 and 0.71, respectively). Finally, we performed macrophage-targeted molecular imaging to
explore a link between inﬂammation and osteoporosis in vivo. Although macrophage burden, visualized as uptake
of NIRF-conjugated iron nanoparticles, was directly related to the degree of arterial and valvular inﬂammation and
calciﬁcation, the same method inversely correlated inﬂammation with TMD (R
2 ¼ 0.73; 0.83; 0.75, respectively).
Conclusion This study provides direct in vivo evidence that in arteries and aortic valves, macrophage burden and calciﬁcation
associate with each other, whereas inﬂammation inversely correlates with bone mineralization. Thus, understanding
inﬂammatory signalling mechanisms may offer insight into selective abrogation of divergent calciﬁc phenomena.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Clinical studies suggest that cardiovascular calciﬁcation, athero-
sclerosis, and chronic renal disease (CRD) are associated with
osteoporosis.
1,2 Emerging epidemiological evidence shows
age-independent correlation between bone mineral density and
cardiovascular events.
3–5 In limited mouse studies, atherosclerosis
susceptibility corresponds to a reduction in bone mineralization.
6,7
Although these observations suggest common underlying mechan-
isms, the precise nature of the relationship between arterial
calciﬁcation, calciﬁc aortic valve disease, and bone osteogenesis,
as well as reciprocal regulation of these processes, remains
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European Heart Journal (2010) 31, 1975–1984
doi:10.1093/eurheartj/ehq237unknown. The National Heart, Lung, and Blood Institute Working
Group on Calciﬁc Aortic Stenosis has recently underscored the
importance of identifying the relationship between calciﬁcation of
the aortic valve and bone and the reciprocal regulation of these
processes.
8
Arterial and aortic valve calciﬁcation is a signiﬁcant cause of
morbidity and mortality.
9,10 Arterial calciﬁcation not only
weakens vasomotor responses, but also affects atherosclerotic
plaque stability. Emerging evidence suggests that atherosclerotic
plaques are prone to rupture, particularly in regions of high back-
ground stress with microcalciﬁcations located in the thin ﬁbrous
cap.
11–13 In addition, calciﬁcation impairs the movement of
aortic valve leaﬂets, causing life-threatening aortic stenosis and
heart failure.
14 Recent studies suggest that underlying mechanisms
of aortic valve calciﬁcation resemble those of atherosclerotic
arterial calciﬁcation, triggered by haemodynamic stress, reactive
oxygen species, and inﬂammatory cues.
14–17
Cardiovascularcalciﬁcationwasconventionallyviewedasaninevi-
table consequence of ageing, but recent landmark studies have
demonstrated that it is a highly regulated process of mineralization,
akin to embryonic bone formation.
14,18 Indeed, calciﬁed vascular
material is often indistinguishable from bone, and its formation
involves cellular and molecular signalling processes found in
normal osteogenesis.
19,20 We have reported that valvular
myoﬁbroblast-like cells, due to their plasticity, respond to various
stimuli by undergoing activation and sequential phenotypic differen-
tiation. During cardiovascular calciﬁcation, macrophage-derived
proteinases such as elastolytic cathepsins or metalloproteinases
induce the release of biologically active, soluble elastin-derived pep-
tides that may promote the osteogenic differentiation of myoﬁbro-
blasts or smooth muscle cells (SMC).
21 This ﬁnding concurs with
studiesofphenotypicconversionofvascularSMCandvalvularmyo-
ﬁbroblastsintoosteoblasticcells,characterizedbytheexpressionof
bone-regulating proteins and osteogenic factors (e.g. alkaline phos-
phatase, osteopontin, osteocalcin, Runx2/Cbfa1, Osterix).
16,22,23
Imaging approaches that can spatially resolve and quantify the
temporal pro-osteogenic molecular processes in arteries, valves,
and bones are limited. Conventional imaging modalities can identify
advanced late-stage calciﬁcation, but optical molecular imaging can
detect tissue mineralization at the earliest stages. The present
study tested the hypothesis that arterial and aortic valve calciﬁca-
tion is inversely correlated with low bone tissue mineral density
(TMD). The speciﬁc objective was to quantify the relationship
between cardiovascular calciﬁcation (arterial and valvular) and
long bone remodelling (cortical and trabecular) in established
models of atherosclerosis and CRD,
14–16 using optical molecular
imaging and high-resolution 3D micro-computed tomography
(CT). In addition, to demonstrate the association between inﬂam-
mation, ectopic calciﬁcation, and osteoporosis, we directly com-
pared macrophage burden and progression of osteogenic
changes in each region of the same animals in vivo and ex vivo.
Our results on opposing effects of inﬂammation in soft tissues (car-
diovascular organs) and in bone agree with the previous reports on
accelerated osteolysis in inﬂamed bones.
24 Our study provides
new insight into the relationship between osteoporosis and cardi-
ovascular calciﬁcation and suggests shared inﬂammatory mechan-
isms of ectopic calciﬁcation and bone osteolysis. It also offers a
unique model for exploration of in vivo mechanisms regulating
early cardiovascular calciﬁcation and bone mineral loss.
Methods
An expanded Methods section is provided in the Supplementary
material online.
Animal protocol
We studied osteogenic changes in carotid arteries, aortic valves, and
femur bones obtained from 30-week-old apoE
2/2 mice (n ¼ 10)
and mice with CRD (n ¼ 10), induced by 5/6 nephrectomy. Age-
matched wild-type C57/BL6 mice (WT, n ¼ 8) served as controls.
At 30 weeks of age, mice underwent intravital microscopy and were
euthanized for ex vivo imaging, followed by histology and statistical ana-
lyses. In addition to molecular imaging, the femurs of the mice under-
went quantitative micro-CT imaging analyses. The Subcommittee on
Research Animal Care at Massachusetts General Hospital approved
all procedures.
Molecular imaging agents
To image osteogenesis, we used imaging agent (Osteosense680/
OS680, VisEn Medical, Inc., Woburn, MA, USA) binding to hydroxy-
apatite in actively mineralized regions containing osteoblast-like cells
in arteries, valves
14–16 (Supplementary material online, Figure S1A),
and bones.
25 Macrophage-targeted near-infrared (NIR)-conjugated
iron nanoparticle (Supplementary material online, Figure S1B) was
used to detect inﬂammation.
14–16
Statistical analyses
Data are presented as mean + standard deviation. Statistical analyses
for comparison groups employed one-way ANOVA, followed by the
Tukey–Kramer post hoc test performed with GraphPad prism software
(version 4.0, GraphPad Software, San Diego, CA, USA). Tests were
two-sided and adjusted for variance inequality where appropriate.
Linear regression with Pearson’s correlation test was used to deter-
mine the covariant relationships between data. Normal distribution
of the data was conﬁrmed by comparing against expected normal dis-
tributions with given means and standard deviation. In all cases, test
probability values less than 0.05 were considered statistically
signiﬁcant.
Results
Serum phosphate, creatinine, cystatin
C, and cholesterol levels in apoE
2/2 and
chronic renal disease apoE
2/2 mice
Total cholesterol was signiﬁcantly increased in apoE
2/2 and CRD
apoE
2/2 mice, when compared with WT mice (467.2+51.1 and
397.1+24.8 mg/dL vs. 56.3+9.8 mg/dL; P , 0.05). In addition,
CRD apoE
2/2 mice had signiﬁcantly increased serum phosphate,
creatinine, and cystatin C levels when compared with apoE
2/2
and WT mice (phosphate: 11.4+0.9 vs. 6.3+0.4 and 4.7+
0.4 mg/dL; P , 0.05; creatinine: 0.6+0.04 vs. 0.4+0.01 and
0.3+0.01 mg/dL; P , 0.05; cystatin C: 0.9+0.01 vs. 0.6+0.2
and 0.3+0.02 mg/mL; P , 0.001). Greater serum phosphate, crea-
tinine, and cystatin C levels suggest that 5/6 nephrectomy induced
kidney failure, which in turn promotes inﬂammation.
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J. Hjortnaes et al. 1976Osteogenic activity in mouse arteries and
aortic valves associate with each other
and increase with atherosclerosis severity
Fluorescence reﬂectance imaging was used to map mineralization
in aortas of WT, apoE
2/2, and CRD apoE
2/2 mice. Strong
signals were detected at the levels of aortic valve, aortic root,
aortic arch, and abdominal aorta, in apoE
2/2 and especially CRD
apoE
2/2 mice when compared with WT mice (Supplementary
material online, Figure S2). Intravital imaging of carotid arteries
in vivo showed more than 47- and 78-fold increases of calciﬁed
tissue area (ROI) in apoE
2/2 and CRD apoE
2/2 mice, respectively,
compared with WT cohort (Figure 1A and B). In addition, up to
100- and 400-fold increases in osteogenic signal intensity (SI)
occurred in apoE
2/2 and CRD apoE
2/2 mice, respectively,
when compared with the WT cohort (Figure 1A and C). Imaging
analyses of the aortic valves in WT, apoE
2/2, and CRD apoE
2/2
mice revealed that ROI increased 4- and 20-fold in size in
apoE2/2 and CRD apoE
2/2 mice, respectively, compared with
ROI in WT mice (Figure 1D and E). Osteogenic SI was further sig-
niﬁcantly increased in aortic valves of apoE
2/2 and CRD apoE
2/2
mice (13- and 50-fold, respectively) when compared with WT
mice (Figure 1D and F). We performed a correlative analysis, in
addition to Pearson’s correlation test, to evaluate an association
between vascular and valvular calciﬁcation. Figure 1G shows a sig-
niﬁcant correlation of arterial and aortic valve calciﬁc ROI
(r ¼ 0.75; P , 0.05). In addition, arterial osteogenic SI signiﬁcantly
correlated with valvular SI (r ¼ 0.67; P , 0.05; Figure 1H).
Figure 1 Induction of osteogenesis in carotid arteries and aortic valves of apoE
2/2 and chronic renal disease apoE
2/2 mice, detected by
intravital fluorescence microscopy. (A) Calciﬁed regions (region of interest) and mineralization (signal intensities) in the carotid arteries of
WT, apoE
2/2, and chronic renal disease apoE
2/2 mice injected with Osteosense680 (maximum signal intensity shown in red). (B) Quantitative
assessment of region of interest showed a signiﬁcant increase in calciﬁcation in the chronic renal disease apoE
2/2 vs. WT and apoE
2/2 mice.
(C) Arterial osteogenic signal intensity is greater in the chronic renal disease apoE
2/2 mice, compared with other groups. (D) Pseudo-colour
mapping of mineralization region of interest and signal intensity in the aortic valves. Aortic valve calciﬁed region of interest (E) and osteogenic
signal intensity (F) are signiﬁcantly higher in the chronic renal disease apoE
2/2 mice, compared with other groups. (A–F)W T ,n ¼ 8; apoE
2/2,
n ¼ 10; chronic renal disease apoE
2/2, n ¼ 10. (G) Correlation of arterial and valve calciﬁed tissue area (region of interest; pixels). (H)C o r -
relation of arterial and valve osteogenic activity (signal intensity; AU). (G and H)W T ,n ¼ 3; apoE
2/2, n ¼ 4; chronic renal disease apoE
2/2,
n ¼ 4.
Ectopic calciﬁcation vs. osteoporosis 1977Figure 2 Loss of bone mineral density and alterations in microarchitecture in mouse femurs, detected by 3D micro-computed tomography
and molecular imaging. (A) Fluorescence microscopy of mid-shaft region of femurs of mice injected with Osteosense680. (B) Quantiﬁcation
analysis of bone mineralization signal intensity showed a signiﬁcant reduction in the chronic renal disease apoE
2/2 mice, compared with
other groups. (A and B)W T ,n ¼ 8; apoE
2/2, n ¼ 10; chronic renal disease apoE
2/2, n ¼ 10. (C and D) Micro-computed tomography
imaging of femur mid-shaft region (normal bone ¼ red; loss of bone mineralization ¼ green–blue). (E) Quantiﬁcation assessment of bone
tissue mineral density shows signiﬁcant bone loss in the apoE
2/2 and chronic renal disease apoE
2/2 mice. (F) Cortical/marrow area shows
a tendency towards a decrease in the cortical/marrow ratio in the chronic renal disease apoE
2/2 mice. (G and H) Micro-computed tomography
imaging of femur head. Quantiﬁcation assessment of microarchitecture demonstrates (I) the decrease in trabecular number and (J) the increase
in trabecular spacing in the chronic renal disease apoE
2/2 mice. (K) No changes in trabecular thickness were detected. (C–K)W T ,n ¼ 3;
apoE
2/2, n ¼ 4; chronic renal disease apoE
2/2, n ¼ 4.
J. Hjortnaes et al. 1978Furthermore, correlative histopathology corroborated our imaging
data (Supplementary material online, Figure S3A and B). These
imaging and histological results support the association between
arterial and aortic valve calciﬁcation.
Bone mineralization decreases in femurs
of atherosclerotic mice and inversely
correlates to arterial and aortic valve
calciﬁcation
Figure 2 shows mineralization in the mid-shaft region of femurs in
WT, apoE
2/2, and CRD apoE
2/2 mice, detected by molecular
imaging ex vivo. We observed signiﬁcantly decreased osteogenic
SI in apoE
2/2 mice and CRD apoE
2/2 mice when compared
with WT mice and in apoE
2/2 mice when compared with CRD
apoE
2/2 mice (Figure 2A and B). Micro-CT imaging further
showed a decrease in bone TMD in the mid-shaft region of
femurs from apoE
2/2 mice when compared with WT mice
(Figure 2C–F), which supports our molecular imaging results.
Quantitative analyses demonstrated a signiﬁcant difference in
TMD between apoE
2/2 mice and WT mice and between CRD
apoE
2/2 mice and WT mice (Figure 2E). Albeit not signiﬁcant
(P ¼ 0.057), the difference between CRD apoE
2/2 mice and
WT mice showed a tendency towards decreased cortical/
marrow area ratio in CRD apoE
2/2 mice, suggesting more
severe loss of bone structure in the CRD cohort (Figure 2F). Peri-
osteal perimeters were not different between conditions,
suggesting that the endosteal dimensions expanded through osteo-
clast activity. Micro-CT showed a decrease in TMD in the femur
heads of apoE
2/2 mice when compared with WT mice
(Figure 2G and H), though bone volume fraction was not signiﬁ-
cantly changed (Supplementary material online, Figure S4).
Further statistical analyses of trabecular microarchitecture
showed a signiﬁcant decrease in trabecular number (Figure 2I)
and a signiﬁcant increase in trabecular spacing (Figure 2J)
between CRD apoE
2/2 mice and WT mice, but there was no sig-
niﬁcant difference in trabecular thickness between groups
(Figure 2K). These results suggest that osteoporotic remodelling
may occur as a consequence of calciﬁc cardiovascular disease.
To test this, we applied a linear regression analysis comparing
arterial and valvular calciﬁcation with bone TMD (Figure 3).
Tissue mineral density inversely correlates with the arterial and
aortic valve regions of calciﬁcation (ROI: R
2 ¼ 0.86 and 0.34;
respectively; Figure 3A and B). Furthermore, TMD is inversely cor-
related to osteogenic SI in carotid arteries and aortic valves (SI:
R
2 ¼ 0.67 and 0.72, respectively; Figure 3C and D). These data
Figure 3 Inverse correlation of bone tissue mineral density with arterial and aortic valve calciﬁcation. Relationship of bone tissue mineral
density to arterial (A) and valve (B) calciﬁed area (region of interest). Relationship of tissue mineral density to arterial (C) and valve (D) osteo-
genic activity (signal intensity). n ¼ 11.
Ectopic calciﬁcation vs. osteoporosis 1979suggest a strong inverse correlation between cardiovascular calci-
ﬁcation and bone mineralization.
Enhanced inﬂammation correlates with
calciﬁcation in arteries and aortic valves
Macrophage-targeted molecular imaging agent (CLIO750) showed
negligible inﬂammatory signal in WT arteries, which was substan-
tially increased in apoE
2/2 and CRD apoE
2/2 mice (Figure 4A).
Quantitative assessment of arterial inﬂammatory ROI determined
a 44- and 95-fold increases in inﬂammation tissue area in
apoE
2/2 mice and CRD apoE
2/2 mice when compared with
WT mice, which was further conﬁrmed with signiﬁcant 326- and
718-fold increases in SI (Figure 4B and C). Likewise, the enhanced
expression of inﬂammation was found in the aortic valves of
apoE
2/2 and CRD apoE
2/2 mice (Figure 4D). Quantitative ana-
lyses demonstrated statistically signiﬁcant increases in inﬂammatory
valvular ROI and SI between WT, apoE
2/2, and CRD apoE
2/2
Figure 4 Induction of inﬂammatory signal in carotid arteries and aortic valves of apoE
2/2 and chronic renal disease apoE
2/2 mice, detected
by intravital fluorescence microscopy. (A) Intravital microscopy detected CLIO750-derived inﬂammatory signals in the carotid arteries of mice.
(B) Signiﬁcant increase in arterial inﬂammation area (region of interest) and (C) inﬂammatory signal intensity in the chronic renal disease
apoE
2/2 mice vs. WT and apoE
2/2 mice. (D) Fluorescence microscopy detected CLIO750-derived inﬂammatory signals in the aortic
valves. (E) Signiﬁcant increase in the aortic valve inﬂammation area (region of interest) and (F) signal (signal intensity) in the chronic renal
disease apoE
2/2 mice, compared with WT and apoE
2/2 mice. (A–F)W T ,n ¼ 8; apoE
2/2, n ¼ 10; chronic renal disease apoE
2/2, n ¼ 10.
(G) Relationship between arterial inﬂammation area (CLIO750; region of interest) and arterial calciﬁed tissue area (Osteosense680; region
of interest). (H) Association of arterial inﬂammatory activity (CLIO750; signal intensity) with arterial osteogenic activity (Osteosense680;
signal intensity). (I) Relationship between valvular inﬂammation (CLIO750; region of interest) and aortic valve calciﬁcation (Osteosense680;
region of interest). (J) Association of valvular inﬂammatory signal (CLIO750; signal intensity) with valvular osteogenic activity (Osteosense680;
signal intensity). (G–J) n ¼ 14.
J. Hjortnaes et al. 1980groups (ROI: 1.5- and 5.7-fold increases, Figure 4E; SI: 2.6- and
11.6-fold increases, Figure 4F). Further, we found a statistically sig-
niﬁcant correlation between cardiovascular calciﬁcation and
inﬂammation in both arteries (ROI: R
2 ¼ 0.73; SI: R
2 ¼ 0.54;
Figure 4G and H) and valves (ROI: R
2 ¼ 0.84; SI: R
2 ¼ 0.81;
Figure 4I and J). Macrophage staining conﬁrmed our molecular
imaging ﬁndings (Supplementary material online, Figure S5A and
B). Overall, these results suggest that the extent of cardiovascular
inﬂammation correlates with the severity of calciﬁcation.
Long bone inﬂammation correlates
inversely with decreased bone mineral
signal and associates positively with
cardiovascular calciﬁcation
Evidence suggests that inﬂamed or infected bones shift towards an
osteolytic environment. To address further the mechanisms for
osteoporotic changes, we attempted to link inﬂammation and
TMD in the same mice used for imaging of cardiovascular calciﬁca-
tion. Molecular imaging demonstrated robust inﬂammation signal in
the long bones of both apoE
2/2 mice and CRD apoE
2/2 mice,
whereas WT mice demonstrated virtually no inﬂammation
(Figure 5A). Using the same approach as before, we found
7.6- and 22-fold increases in long bone inﬂammation (CLIO SI)
for apoE
2/2 mice and CRD apoE
2/2 mice, when compared
with WT mice (Figure 5B). In contrast to the cardiovascular con-
dition, this increased inﬂammation correlated with decreased
bone mineral signal (R
2 ¼ 0.75; Figure 6A). These results strongly
suggest that the inﬂammatory responses in long bones contribute
to loss of bone mineralization. Finally, we found strong positive
correlations in SI between the degree of arterial or valvular inﬂam-
mation and bone inﬂammation (R
2 ¼ 0.97; Figure 6B and C). These
results support our hypothesis that systemic inﬂammatory signal
simultaneously acts to decrease bone mass and increase cardiovas-
cular calciﬁcation.
Discussion
This study establishes direct in vivo evidence that the calciﬁcation of
arteries and aortic valves in atherosclerosis and CRD correlates
inversely with bone tissue mineralization. We demonstrate an
association between aortic valve calciﬁcation and arterial calciﬁca-
tion and that the degree of cardiovascular calciﬁcation correlates
directly with the loss of bone mineral. The increased inﬂammatory
activity in arteries, aortic valves, and long bones in atherosclerosis
and renal failure demonstrate that inﬂammation at these three
locations is related probably via systemic or circulating inﬂamma-
tory cues. Furthermore, our study reveals that whereas macro-
phage burden positively correlates with the extent of early
cardiovascular calciﬁcation, inﬂammation inversely associates with
bone mineralization. These results build on previous studies of
the pathogenesis of cardiovascular calciﬁcation, in which advanced
molecular imaging approaches demonstrated that atherosclerotic
and aortic valve calciﬁcation share similar risk factors and are
induced by similar pro-inﬂammatory molecular and cellular pro-
cesses.
14–16 Our seemingly paradoxical in vivo evidence on inﬂam-
mation and bone mineralization concur well with previous reports
on osteolytic environment in inﬂamed bones.
24
Arterial calciﬁcation occurs in two different forms: intimal calci-
ﬁcation, typically associated with atherosclerosis, and medial calci-
ﬁcation, an ossiﬁcation process associated with renal failure and
diabetes.
9 In dysmetabolic patient populations, both types of arter-
ial calciﬁcation often develop simultaneously. Intimal calciﬁcation
increases the risk of plaque rupture, whereas medial calciﬁcation
increases arterial stiffness and impairs cardiovascular haemody-
namics.
9 Although the mechanism remains incompletely
Figure 5 Correlation of long bone inﬂammation with osteogenic activity. (A) Molecular imaging of inﬂammation in the long bones of mice
injected with CLIO750. (B) Signiﬁcant increase in bone inﬂammation in the chronic renal disease apoE
2/2 mice vs. WT and apoE
2/2 mice.
(A and B)W T ,n ¼ 8; apoE
2/2, n ¼ 10; chronic renal disease apoE
2/2, n ¼ 10.
Ectopic calciﬁcation vs. osteoporosis 1981understood, it is generally agreed that cardiovascular calciﬁcation is
a more active biological process than previously considered.
26
Clinicopathological studies have shown similarity between calciﬁed
vascular material and bone material,
20 have observed osteoblasts
and osteoclast-like cells in the arterial wall,
19 and have
demonstrated the presence of various bone-regulating proteins
in calciﬁed arteries.
27 Osteogenic differentiation of vascular SMC
or valvular myoﬁbroblasts is likely caused by various mechanisms,
including pro-inﬂammatory cytokines (e.g. IL-6, TNF-a),
10 oxidized
lipids,
17 and microenvironmental and mechanical cues.
28 Biochemi-
cal imbalances also accelerate calciﬁcation. Studies show that
excess phosphate levels in CRD accelerate calciﬁcation of vascular
SMC or valvular myoﬁbroblasts through the phosphate-induced
release of matrix vesicles and apoptosis.
15,29
Systemic factors associated with CRD, including reduced circu-
lating levels of erythropoietin, have been shown to reduce osteo-
blast quantity and bone mineral density via Jak-Stat signalling in
haematopoietic stem cells.
30 Furthermore, the kidneys represent
the site of vitamin D activation, and therefore CRD-associated
reductions in activated vitamin D may also induce parallel
reductions in bone mass. Whether CRD-induced anaemia or acti-
vated vitamin D deﬁciency plays a role in the reduced bone mass
or increased cardiovascular calciﬁcation remains uncertain.
Our results directly quantiﬁed a paradox of simultaneous osteo-
lysis and ectopic calciﬁcation in vivo in the same animals. Although
both correlate with age in humans, some clinical studies have
shown the association of cardiovascular calciﬁcation and osteo-
porosis to be independent of age.
3,31 Research has demonstrated
that patients with lower bone density and osteoporosis have
more severe atherosclerosis.
32,33 Dyslipidaemia also may link
bone loss with cardiovascular calciﬁcation. Pre-clinical studies
suggest that hyperlipidaemia reduces bone mineral density
34 and
promotes arterial and valvular calciﬁcation in mice
14,16 and that
Figure 6 Relationship between bone osteogenic activity and
inﬂammation. (A) Inverse association of bone osteogenic activity
(Osteosense680; signal intensity) with bone inﬂammation
(CLIO750; signal intensity). (B) Positive relationship between
arterial inﬂammation (CLIO750; signal intensity) and bone inﬂam-
mation (CLIO750; signal intensity). (C) Positive correlation of
aortic valve inﬂammation (CLIO750; signal intensity) and bone
inﬂammation (CLIO750; signal intensity). (A–C)W T ,n ¼ 8;
apoE
2/2, n ¼ 10; chronic renal disease apoE
2/2, n ¼ 10.
Figure 7 Schematic presentation of a hypothetical model on
the paradoxical relationship between cardiovascular calciﬁcation
and bone mineral loss, associated with local and systemic inﬂam-
mation. Atherosclerosis and chronic renal disease-associated sys-
temic inﬂammatory stimuli enhance local inﬂammation in the
cardiovascular system. Local pro-inﬂammatory microenviron-
mental cues in atherosclerotic plaques and diseased valves may
shift vascular and valvular cells towards an osteogenic phenotype,
resulting in increased mineral deposition. In the bone, the inﬂam-
matory milieu may increase the number/activity of bone-
resorbing osteoclasts, leading to decreased mineral. Additional
factors arising from bone could further inﬂuence cardiovascular
calciﬁcation.
J. Hjortnaes et al. 1982statins reduce calciﬁcation.
14,35 Moreover, loss of bone mass leads
to increased circulating phosphate and calcium and decreased
parathyroid hormone, which stimulate the Cbfa1-dependent min-
eralization of cardiovascular tissue.
36 This evidence suggests that
osteoporosis may contribute to cardiovascular calciﬁcation by
adding to a pathological microenvironment that promotes osteo-
genesis of the arterial wall and aortic valve. During bone resorp-
tion, biochemical factors are released into the circulation,
contributing to vascular calciﬁcation; this observation agrees with
studies showing that agents that block bone resorption in animal
models also block vascular calciﬁcation.
37
Our ﬁndings strongly suggest in vivo that systemic and local
inﬂammation drives both cardiovascular calciﬁcation and bone
loss. In general, inﬂammation causes ‘hardening’ of soft tissue and
‘softening’ of hard tissue,
34 but it is unclear whether the pathways
are similar. Connections between inﬂammation and osteolysis
were recently established in arthritic and periodontal diseases.
24
Pro-inﬂammatory cytokines such as IL-6 and TNF-a have been
shown to increase the osteoclast activity through the NF-kB
pathway.
38 Osteoprotegerin, normally produced by vascular SMC
and osteoblasts, functions as a decoy receptor for the receptor
activator of NF-kB ligand RANKL.
26 RANKL, a cytokine that
induces osteoclast differentiation and activation, stimulates bone
resorption, whereas osteoprotegerin neutralizes the binding of
RANKL to RANK and prevents bone loss. Osteoprotegerin-
deﬁcient mice demonstrated severe bone loss in addition to
medial calciﬁcations.
39 Taken together, these studies suggest that
inﬂammation in cardiovascular and bone regions acts through the
NF-kB–RANKL pathway, but whether this pathway is utilized sim-
ultaneously for ectopic calciﬁcation and bone loss is unknown.
Figure 7 shows a schematic illustration of our working hypothesis.
The presence of atherosclerosis or CRD likely associates with sys-
temic inﬂammatory signals, as described above. Local inﬂammation,
as detected by macrophage-targeted NIR ﬂuorescence nanoparti-
cles, associates with increased mineral in cardiovascular tissues and
decreased mineral in bone, as detected by Osteosense. Potential
mediators associated with systemic and local inﬂammatory pro-
cesses are shown, as are possible factors arising from bone, which
could further inﬂuence cardiovascular calciﬁcation. Studies are
needed to further establish the relationship between cardiovascular
calciﬁcation and osteoporosis and to dissect the complex mechan-
isms for reciprocal regulation of these processes.
Unravelling the mechanisms underlying cardiovascular calciﬁca-
tion is an important step towards future strategies. Therapeutic
agents that selectively increase or inhibit osteogenesis will be
much preferred over current systemic approaches such as statin
therapy. The identiﬁcation of high-risk patients at subclinical
stages is an equally important task, requiring new imaging modal-
ities or biomarkers targeting calciﬁcation.
8 Molecular imaging pro-
vides appealing new means to identify early-stage calcifying
atherosclerotic plaques and aortic valve lesions and offers a
powerful tool in personalized preventive cardiovascular medicine.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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